Maze Therapeutics refuels with another $190M to prove its genetic modifiers approach holds up in the clinic

Nicole DeFeudis

Editor

Jason Coloma remembers when Maze Therapeutics was nothing more than a bunch of PowerPoint slides. Several months after revealing exactly what his team of scientists …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Maze Therapeutics refuels with another $190M to prove its genetic modifiers approach holds up in the clinic

Nicole DeFeudis

Editor

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Maze Ther­a­peu­tics re­fu­els with an­oth­er $190M to prove its ge­net­ic mod­i­fiers ap­proach holds up in the clin­ic

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Maze Therapeutics refuels with another $190M to prove its genetic modifiers approach holds up in the clinic

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Outlook's shares crash as wet AMD drug flunks Phase 3 test